Sonnet BioTherapeutics effects 1-for-22 reverse stock split effective August 31, 2023

Sonnet BioTherapeutics Holdings, Inc.

Every 22 pre-split shares converted to 1 post-split share; no fractional shares issued, cash paid in lieu.
Reverse split effective at 4:30 p.m. ET on August 31, 2023; trading on split-adjusted basis starts September 1.
CUSIP number changed to 83548R303; par value and authorized shares unchanged.
Stock options, warrants, and convertible securities adjusted proportionally.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Sonnet BioTherapeutics Holdings, Inc.: Filed Certificate of Amendment to effect a 1-for-22 reverse stock split of common stock, effective at 4:30 pm ET on August 31, 2023 (effective 2023-08-31).

Change: charter amendment
Effective: 2023-08-31

Exact text from the filing

On August 31, 2023 (the “ Effective Date ”), Sonnet BioTherapeutics Holdings, Inc. (the “ Company ”) filed a Certificate of Amendment to the Company’s Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “ Certificate of Amendment ”), which effected, at 4:30 p.m. Eastern Time on August 31, 2023, a one-for-twenty two reverse stock split (the “ Reverse Stock Split ”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “ Common Stock ”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001493152-23-031408

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.